A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer

Exclusion Criteria

• •1. Received anti-tumor treatment such as chemotherapy, radiotherapy, immunotherapy, biotherapy or other clinical research drugs within 4 weeks before the first administration;
• •2. Other active malignancies within 5 years or at the same time;
• •3. Subjects with a history or evidence of brain metastasis or meningeal metastasis;
• •4. With acute or chronic uncontrolled pancreatitis or Child-Pugh liver function grade C;
• •5. Severe trauma or major surgery was performed within 4 weeks before the first administration;
• •6. To study the severe heart disease within 6 months before the first administration;
• •7. Patients with clinical symptoms and uncontrolled moderate and above pleural effusion, ascites or pericardial effusion, requiring therapeutic puncture drainage;
• •8. Severe infection symptoms occurred within 2 weeks before the first administration;
• •9. Known hereditary or acquired bleeding and thrombotic tendency;
• •10. Congenital or acquired immune defects;
• •11. The subjects had severe and uncontrollable concomitant diseases;
• •12. Cerebral infarction, pulmonary embolism or deep vein thrombosis occurred within 6 months before the first administration of the study.